Jiangsu Hengrui Medicine Company Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Xiaoxing Huang

Lianshan Zhang

Changyong Yang

Guoqing Cao

Cheng Liao

Xiaohua Wu

Qing Yang

Dingwei Ye

Quanren Wang

The present disclosure provides the use of an anti-PD-1 antibody in combination with famitinib in the preparation of a drug for treating tumors. In the present technical solution, toxicity is controllable and tolerable. At the same time, the described drug combination effectively reduces adverse reactions to the anti-PD-1 antibody, such as the occurrence of reactive capillary endothelial proliferation.

Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors

Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description. 

Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain

Growing community of inventors

Jiangsu, China

Xiaoxing Huang